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Reducing the metabolic cost of walking
with an ankle exoskeleton: interaction
between actuation timing and power
Samuel Galle1*† , Philippe Malcolm1,2†, Steven Hartley Collins3 and Dirk De Clercq1

Abstract
Background: Powered ankle-foot exoskeletons can reduce the metabolic cost of human walking to below normal
levels, but optimal assistance properties remain unclear. The purpose of this study was to test the effects of
different assistance timing and power characteristics in an experiment with a tethered ankle-foot exoskeleton.
Methods: Ten healthy female subjects walked on a treadmill with bilateral ankle-foot exoskeletons in 10 different
assistance conditions. Artificial pneumatic muscles assisted plantarflexion during ankle push-off using one of four
actuation onset timings (36, 42, 48 and 54% of the stride) and three power levels (average positive exoskeleton
power over a stride, summed for both legs, of 0.2, 0.4 and 0.5 W∙kg−1). We compared metabolic rate, kinematics
and electromyography (EMG) between conditions.
Results: Optimal assistance was achieved with an onset of 42% stride and average power of 0.4 W∙kg−1, leading to
21% reduction in metabolic cost compared to walking with the exoskeleton deactivated and 12% reduction
compared to normal walking without the exoskeleton. With suboptimal timing or power, the exoskeleton still
reduced metabolic cost, but substantially less so. The relationship between timing, power and metabolic rate was
well-characterized by a two-dimensional quadratic function. The assistive mechanisms leading to these
improvements included reducing muscular activity in the ankle plantarflexors and assisting leg swing initiation.
Conclusions: These results emphasize the importance of optimizing exoskeleton actuation properties when
assisting or augmenting human locomotion. Our optimal assistance onset timing and average power levels could
be used for other exoskeletons to improve assistance and resulting benefits.
Keywords: Human locomotion, Augmentation, Lower-limb exoskeletons, Metabolic cost, Optimal assistance

Background
Walking is the most frequent means of human locomotion [1]. While humans use many strategies to reduce
energy expenditure [2], walking still requires a considerable amount of metabolic energy, sometimes referred to
as the ‘metabolic cost’ of walking. Assisting the ankle
joint with an exoskeleton can reduce the metabolic cost
of walking to below the cost of normal walking [3–6].
This shows that it is possible to reduce metabolic cost
through robotic assistance.
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Reductions in the metabolic cost of walking with
ankle-foot exoskeletons result from two competing factors. A benefit can be derived from the exoskeleton
when it acts to assist gait, expressed as the difference between powered exoskeleton1 walking and walking in
zero-work mode1. However, wearing the exoskeleton in
zero-work mode typically results in a metabolic penalty,
expressed as the difference between normal walking1
without an exoskeleton and walking in zero-work mode.
Some full-body exoskeletons have resulted in large metabolic penalties (e.g. [7]) while lightweight ankle-foot exoskeletons have resulted in penalties of less than 3% for
active autonomous1 exoskeletons [4] and even close to
zero for passive autonomous1 exoskeletons [5]. Reducing
the penalty of wearing an exoskeleton in zero-work
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mode is mainly a design challenge, while increasing the
difference between the zero-work condition and powered
exoskeleton conditions is mainly a biomechanics challenge.
In order to solve the latter human-exoskeleton interaction challenge, optimal assistance properties (e.g. actuation timing, assistance magnitude, etc.) are crucial to
further reduce the metabolic energy cost of walking.
Malcolm et al. [3] showed that the timing of exoskeleton
actuation onset (referred to as actuation timing) is an
important exoskeleton property that influences the
metabolic cost of walking with active exoskeletons. They
found a convex landscape in metabolic cost versus actuation timing with an optimum around 40% of the stride.
Studies that have found the highest reductions in metabolic energy cost have also used an actuation timing
around 40% of the stride [4, 6].
Of course, actuation timing is not the only determinant of metabolic cost when walking with ankleexoskeleton assistance. Assistance magnitude also
seems to have a strong effect [8, 9]. The average positive mechanical exoskeleton power per stride summed
for both ankles (referred to here as exoskeleton power)
can be as high as 0.38 W∙kg−1 resulting in reductions
in net metabolic cost of between 10 and 22% for powered exoskeleton conditions compared to zero-work
conditions [3, 4, 6, 8, 10–12]. However, comparing
these studies does not result in a clear relationship between exoskeleton power magnitude and metabolic
cost, likely because many factors differ between studies (e.g. design, exoskeleton mass, actuation profile,
etc.), confounding comparisons. The simplest walking
model [13] would suggest that increasing exoskeleton
power will reduce the mechanical energy requirements
for walking until subjects walk with zero metabolic
cost. Indeed, a recent study, in which both ankle and
hip joints were assisted with a soft exo-suit [8] indicated that metabolic energy cost reduces linearly with
increasing exoskeleton assistance magnitude, similar
to some findings with active prostheses [9]. On the
other hand, a study on unilateral exoskeleton assistance suggested an exponential relationship between
device power and metabolic cost [14]. Experiments
and simulation studies with exoskeletons have similarly suggested that under some conditions “more is
not always better” [5, 15, 16]. Interpretations have
been made more difficult by the limited range of attainable levels of exoskeleton power, which has often been between 50 and 80% of biological ankle power [4, 10, 11].
In order to study if and when the reduction in the
metabolic cost of walking begins to level-off with increasing exoskeleton power during bilateral exoskeleton
assistance, it seems necessary to deliver more power
than in current studies. To identify the influence of exoskeleton power magnitude on the metabolic cost of
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walking, as well as the interaction with actuation timing,
there is a need for a parametric study of actuation timing and exoskeleton power over a larger range. A study
of both actuation characteristics is also expected to contribute to an improved understanding of the assistive
mechanisms of ankle-foot exoskeletons. Several studies
have indicated that other joints besides the ankle joint
are involved in the reduction in metabolic cost experienced when using an ankle-foot exoskeleton [3–5, 8, 12,
17, 18] but the exact mechanisms are unclear. Exploring
different assistance parameters over a broad range would
help to identify the relationship between biomechanical
changes and the resulting changes in metabolic cost.
The overall goal of this study was to characterize the
relationship between ankle exoskeleton power, actuation
timing, and metabolic cost during walking over a broad
range. We used a tethered and powered plantarflexionassisting exoskeleton to vary actuation onset timing and
average exoskeleton power independently and over a
broad range and studied the influence of these characteristics on the metabolic energy cost of walking. We expected a second-order effect of actuation timing on
metabolic energy cost [3] and explored several candidate
relationships between exoskeleton power and metabolic
energy cost to evaluate the interaction between timing,
power and metabolic cost. A secondary goal was to use
the best relationship to define optimal assistance parameters. Finally, we analyzed muscle activation, exoskeleton
kinetics and walking kinematics that describe the neuromechanical interaction between the exoskeleton and the
human, with the goal of explaining the reduction in
metabolic cost and improving our understanding of
human-exoskeleton interaction.

Methods
Subjects

Fourteen female subjects participated in the experiment
from which ten were retained (age 23 ± 1.2 y; weight
61.0 ± 4.5 kg; height 168.1 ± 5.2 cm; European shoe size
38.6 ± 0.8). Non-inclusions were due to technical failure
of the exoskeleton (two subjects), drop-out (one subject)
and errors in data synchronization (one subject). We selected female subjects of normal height and weight to be
able to use one exoskeleton size for all subjects and to
achieve relatively large amounts of exoskeleton power
normalized to bodyweight. None of the subjects had
prior experience using an exoskeleton. All participants
provided written informed consent prior to participation.
The experimental protocol was approved by the ethical
committee of the Ghent University Hospital.
Exoskeleton

The bilateral exoskeleton (Fig. 1) consisted of an anklefoot orthosis at each leg with a hinge at the ankle joint
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Fig. 1 Schematic representation of the experimental set-up. The exoskeleton (a) has footswitches in the heel to detect foot contact and a load
cell that is mounted proximal to the pneumatic muscle to measure tension. A linear displacement sensor that is connected between the foot
segment and the shank segment measures ankle joint angle for real-time control. During the experiment subjects wore an exoskeleton at each
leg (b) and walked on a treadmill. The pneumatic muscles were activated during ankle push-off and assisted plantarflexion. Subjects wore EMG
electrodes, reflective markers and a face mask for data collection. Not all reflective markers and EMG electrodes are represented in the figure

and pneumatic muscles [3, 17–19]. The pneumatic muscles were 0.27 m in length and were connected between
the foot segment and the shank segment. They
‘contracted’ when inflated with compressed air. The
locations of the pneumatic muscles insertions were individually adjusted such that they allowed 15° of dorsiflexion when passive. The exoskeleton fitted inside standard
sport shoes. Footswitches (Multimec 5E/5G, Mec,
Ballerup, Denmark) were built in to detect foot contact.
Load cells (100 Hz; 210 Series, Richmond Industries
Ltd., Reading, United Kingdom) were connected
between the orthoses and the pneumatic muscles to
measure the force of the pneumatic muscles. Linear displacement sensors (100 Hz; SLS130, Penny&Giles,
Christchurch, United Kingdom) were connected between the foot and shank sections of the exoskeletons to
measure ankle joint angles [20]. The total weight of one
tethered exoskeleton including all sensors was 0.890 kg
(0.680 kg for the orthosis, 0.030 kg for the displacement
sensor, 0.110 kg for the pneumatic muscle and 0.070 kg
for the load cell). Additional hardware, including an air
supply, was placed next to the treadmill.
Actuation timing and exoskeleton power

Based on footswitch signals from the previous stride, exoskeleton actuation for the next stride was controlled using
fixed percentages of stride time with a feedforward algorithm in Labview (National Instruments, Austin, TX, USA)
[3, 17–19]. To control the amount of exoskeleton mechanical power, air pressure in the pneumatic muscles was adjusted using an iterative learning algorithm [9, 21]. For
exoskeleton real-time control, average positive exoskeleton
ankle joint mechanical power was measured in real-time
using the load cell and the linear displacement sensor
(Fig. 1). Based on a prior calibration with motion capture,

ankle joint angle and moment arm of the pneumatic muscles were estimated based on linear displacement [20]. A
moving average of positive exoskeleton power with a window of 10 strides was then used as the input for the iterative learning algorithm. Over the course of many steps, the
algorithm slowly increased or decreased air pressure to the
pneumatic muscles when average power was too low or too
high, respectively, in order to achieve a desired amount of
average exoskeleton power during walking.
Experimental conditions

The experiment consisted of a habituation session and a
data collection session with roughly one week in between. A total of 14 conditions were applied in each session: a NormalWalking condition, in which subjects
walked with normal shoes without an exoskeleton; a
ZeroWork condition, in which subjects walked with the
exoskeleton but without assistance from the pneumatic
muscles; and 12 powered exoskeleton conditions. The 12
powered conditions were based on a two dimensional
parameter sweep of four actuation onset timings (actuation timings) and three average positive exoskeleton
ankle joint mechanical power levels (exoskeleton
powers) (Fig. 2). Four timing values where applied with
actuation onset timing of 36 ± 1%, 42 ± 1%, 48 ± 1% and
54 ± 1% of the stride (referred to as Earliest, Early, Late
and Latest, respectively) and with actuation always ending at 64 ± 1% of the stride. These values were chosen to
be close to the optimal actuation onset timing from a
previous study [3]. Three exoskeleton power levels were
applied, with values of 0.21 ± 0.02 W∙kg−1, 0.41 ±
0.03 W∙kg−1 and the maximum achievable amount with
our exoskeleton and control methods, which was 0.50 ±
0.06 W∙kg−1 (referred to as Low, Medium and High, respectively). These values were chosen based on the
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air pressure substantially during powered exoskeleton conditions on the data collection day.
Data collection

Fig. 2 Parameter sweep of actuation timing and exoskeleton power.
Actuation timing and exoskeleton power for the 10 powered
exoskeleton conditions tested. Dots are population averages and
lines are standard deviations. Each condition resulted in a distinct
combination of timing and power

capabilities of our exoskeleton testbed, and coincided with
approximately 50, 100 and 125% of the net biological
ankle work observed during normal walking [4, 10, 11].
This exceeded the largest range of prior exoskeleton studies [8]. It was not possible to apply more than 0.2 W∙kg−1
with Latest timing due to bandwidth limitations of the
pneumatic actuators. Lower amounts of power with this
timing did not appear to be useful. We therefore chose to
include only 10 powered exoskeleton conditions in our
analysis: three actuation timings (Earliest, Early and Late)
for which three power levels were applied (Low, Medium
and High) and a fourth actuation timing (Latest) for which
only one power level was applied (Low) (Fig. 2).
Experimental protocol

In the habituation session, subjects learned to walk with
the exoskeleton and became accustomed to the experimental set-up. They walked in all powered conditions,
the ZeroWork condition and the NormalWalking condition on the treadmill at 1.25 m∙s−1. All conditions lasted
three minutes with two minutes of rest in between. Conditions were applied in random order, apart from the
NormalWalking condition which was always first or last
due to the time to don and doff the exoskeleton.
Experimental data were collected on a separate day,
about a week later. Each subject performed the same walking protocol as in the habituation session, but conditions
lasted for four minutes to reach steady-state metabolic rate.
A standing rest condition in which subjects stood still for
four minutes was also applied before the walking conditions
to capture resting metabolic rate. Air pressure of the pneumatic muscles at the beginning of each powered condition
was set to be the same as the air pressure from the end of
each powered condition in the habituation session, such
that the iterative learning algorithm did not need to change

Subjects wore a face mask connected to a gas analysis
system that measured O2 consumption and CO2 production continuously (Cosmed, K4b2, Rome, Italy) (Fig. 1).
Exoskeleton sensors (footswitches, displacement sensors
and load cells) also measured continuously during the
entire experiment (Fig. 1). Full body 3D kinematics were
recorded with 51 reflective markers (four on each foot,
two on each exoskeleton foot segment, two on each
exoskeleton ankle joint, six on each exoskeleton shank
segment, two on each knee joint, four on a plate connected to each thigh, six on the pelvis, and five on the
torso) and 14 infrared cameras (200 Hz; Pro Reflex,
Qualisys AB, Gothenburg, Sweden) with Qualisys software. Surface electromyography (EMG) of the m. (Musculus) soleus, m. gastrocnemius medialis, m. tibialis
anterior, m. vastus lateralis, m. rectus femoris, m. biceps
femoris and m. gluteus maximums of both legs were
measured with bipolar surface electrodes and wireless
transmitters (1000 Hz; ZeroWire, Noraxon, Scottsdale,
AZ, USA). Electrodes were placed in accordance with
SENIAM guidelines [22]. For the m. soleus and m. gastrocnemius medialis, holes were cut in the orthosis on the
approximate locations. Marker data and surface EMG data
were collected for 10s during the last minute of each condition, which included around nine full strides.
Data processing

Metabolic energy cost of walking was the primary study
outcome. It was estimated based on O2 consumption
and CO2 production during the last two minutes of each
condition using a standard equation [23]. Net metabolic
cost was calculated by subtracting the metabolic cost of
standing at rest from gross metabolic cost during walking and was normalized to body weight.
All time series data presented in figures were time normalized from heel contact to the next heel contact of the
same leg, averaged for the left and right leg and averaged
across subjects to calculate population stride averages.
Kinematics were analyzed to evaluate the effect of exoskeleton assistance on walking patterns. An eight segment model (two feet, two shanks, two thighs, one
pelvis and one torso) was used to calculate sagittal plane
joint angles with Visual 3D software (C-Motion, MD,
USA). Dempster’s regression equations [24] were used to
define segment masses, with some alterations: the mass
of the arms and head were added to the torso and the
mass of the foot and shank sections of the exoskeleton
were added to the foot and shank segments, respectively,
of the model for the exoskeleton conditions. Heel contact and toe-off were automatically detected using foot
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kinematics [25]. Toe-off timing was expressed as a
percentage of the stride time. Time between consecutive
heel contacts was multiplied with treadmill speed to calculate step length.
Exoskeleton kinetics were calculated to assess actuation
timing and exoskeleton power. Marker positions and pneumatic muscle force data were filtered with a Butterworth
low-pass filter with a cut-off frequency of 12 Hz. Ankle
joint angle and moment arm of the pneumatic muscles
were calculated using motion capture. Ankle joint angular
velocity was calculated as the first derivative of the ankle
joint angle in time. Moment arm of the pneumatic muscle
force was calculated frame-by-frame as the minimum distance between the ankle joint axis and the pneumatic
muscle centroid. Pneumatic muscle force, measured via a
load cell, was multiplied with the moment arm to calculate
exoskeleton torque and multiplied with ankle joint angular
velocity to calculate instantaneous exoskeleton mechanical
power. Actuation onset timing was calculated based on the
maximum of the second derivative of the unfiltered exoskeleton torque, which provides a robust measure of torque
onset [21]. Exoskeleton power was calculated as the numerical integration of positive instantaneous exoskeleton power
over the stride, divided by the stride time and summed for
both legs. We chose to sum average exoskeleton power for
both legs in order to facilitate comparisons to the reduction
in body metabolic rate resulting from assistance.
EMG data were measured to describe the neuromuscular interaction between the exoskeleton and the user.
Surface EMG data were band pass filtered (50–450 Hz)
and rectified. A moving root mean square with a window of 100 ms was then applied. All EMG values were
normalized to the peak value of the ZeroWork condition
so that the peak value in the ZeroWork condition represents a value of 100. For all muscle groups, peak values
were calculated for instances where a clear activation
burst was present in the stride. For the m. tibialis anterior this was the peak value in the beginning of the stance
phase (between 1 and 62% of the stride) and in the beginning of the swing phase (between 62 and 80% of the
stride). For the m. soleus this was the peak value in the
stance phase (between 1 and 62% of the stride) and in
the beginning of the swing phase (between 62 and 80%
of the stride). For the m. gastrocnemius medialis this
was the peak value during the stance phase (between 1
and 62% of the stride). For the m. rectus femoris this
was the peak value in the stance phase (between 1 and
62% of the stride) and the peak value around toe-off (between 40 and 80% of the stride). For the m. biceps
femoris this was the peak value during the swing phase
(between 62 and 100% of the stride). For the m. vastus
lateralis and the m. gluteus maximus this was the peak
value during the stance phase (between 1 and 62% of the
stride).
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Center-of-mass power, which is calculated by the dot
product of center-of-mass velocity and ground reaction
force, can be used to distinguish four functional phases
of stance during walking: collision, rebound, pre-load
and push-off [26, 27]. In prior studies, the rebound
phase has been observed to covary with metabolic cost
[5, 8, 9, 28–30]. Rebound work is calculated as the area
under the positive burst of center-of-mass power during
the single stance phase. It represents the positive centerof-mass work that is done by leg straightening, possible
elastic rebound of the knee, and hip work that moves
the swing leg [26]. We calculated center-of-mass velocity
and acceleration by taking the first and second derivative
of center-of-mass position in the treadmill belt reference
frame. Ground reaction force was estimated based on
center-of-mass acceleration and body mass. This rough
approximation of the ground reaction force can replace
the direct ground reaction force measurement when no
force plate is available [31]. While data from double support could not be usefully interpreted [32], it was possible to retain center-of-mass power during the rebound
phase (positive burst during the single stance phase) and
to calculate average rebound power as the numerical integration of rebound power, divided by stride time. We
expressed average rebound power in W∙kg−1.
Data analysis

To evaluate steady state in metabolic rate measurements, a repeated measures analysis of variance
(ANOVA) was performed between sequential 30s averages from the four minute walking conditions with posthoc paired t-tests (SPSS Statistics 21, IMB, Armonk, NY,
USA). Other statistical analyses were performed with
Matlab (MathWorks, Natick, MA, USA). Repeated measures ANOVA (P ≤ 0.05) were performed to establish differences in metabolic cost, step-time parameters, EMG
metrics and center-of-mass metrics between all conditions. When a statistical difference was found between
conditions, pairwise comparisons were performed using
post-hoc paired t-tests (P ≤ 0.05) to search for differences
between the powered exoskeleton conditions (n = 10)
and the ZeroWork condition and between the powered
exoskeleton conditions (n = 10) and the NormalWalking
condition. We used a Šídák-Holm correction for multiple testing [33] for these 20 comparisons. We did not
compare the 10 powered exoskeleton conditions with
each other using paired t-tests. Instead, when significant
differences were found between one or more powered
exoskeleton conditions and the ZeroWork condition or
between one or more powered exoskeleton conditions
and the NormalWalking condition, we used a regression
analysis to express changes in specific outcome parameters resulting from varying actuation timing and power
magnitude levels.
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A two-dimensional regression was used to describe
overall trends in outcome parameters as the result of
changes in actuation timing and power magnitude. The
reduction in metabolic energy cost compared to the
zero-work condition was chosen as the dependent variable and actuation timing and exoskeleton power were
chosen as independent variables. This regression analysis
was done based on the population averages but we also
calculated individual regressions to illustrate individual
differences (Additional file 1: Figure S1). The regression
analysis was done for 14 cases (10 powered exoskeleton
conditions and four ZeroWork conditions), where the
Zerowork condition was assessed at each timing. Hence,
in the ZeroWork condition the exoskeleton power
equals zero, which was added for the average of every
actuation timing (Earliest, Early, Late, Latest) so that the
surface fit would include the ZeroWork condition for all
actuation timings. Coefficients of determination (R2)
were calculated to evaluate how well the curve fits
matched with the 10 powered conditions and the four
ZeroWork conditions. We performed regressions to several candidate formulae (Table 1). In each formula we
included a second-order relationship between the reduction in metabolic cost and actuation timing based on
previous research [3]. This second-order relationship
was then multiplied by exoskeleton power, reflecting the
expectation that timing would not affect outcomes when
power was zero. For the independent relationship between exoskeleton power and metabolic cost we considered three additional terms: (1) a linear relationship, (2)
a second-order relationship and (3) an exponential relationship. These candidate terms were based on conflicting observations from previous studies [3, 8, 9, 14]. This
resulted in three candidate formulae:
ΔE ¼ a þ b⋅ Pavg þ c⋅Ton⋅Pavg þ d⋅T on2 ⋅Pavg

ΔE ¼ a þ b⋅ Pavg þ c⋅Pavg 2 þ d⋅Ton⋅Pavg
þ e⋅T on2 ⋅Pavg

ð1Þ
ð2Þ

ðc⋅Pavg Þ

ΔE ¼ a þ b⋅ exp
Pavg þ d⋅Ton⋅Pavg
þ e⋅T on2 ⋅Pavg

ð3Þ

Where ΔE is the change in net metabolic cost compared
to the ZeroWork condition (e.g. 0.51 W∙kg−1); Ton is
actuation onset (e.g. 43%); and Pavg is exoskeleton
power (e.g. 0.2 W∙kg−1).
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We identified the coefficients for each formula that resulted in the best fit, i.e. the least residual sum of
squares (Table 1). The coefficients for regression 2 and 3
resulted in very similar coefficients of determination
(R2). Regression 2, with a second order relationship for
both the actuation timing and exoskeleton power determinants, resulted in a slightly higher R2 value. While this
difference is negligible and not sufficient to prefer one of
both regressions, all High exoskeleton power conditions
resulted in a higher metabolic cost compared to the
Medium power conditions (Fig. 4. and Additional file 4:
Figure S4). This suggests that there is not only a
levelling-off in the metabolic cost when high power
magnitude levels are present but that there is even an
optimal exoskeleton power magnitude in our results. As
such, we decided to use regression 2, with a second
order relationship for both the actuation timing and exoskeleton power determinants, for further analysis. Following the metabolic cost, the same fitting method was
then used to relate EMG data to actuation timing and
exoskeleton power:
EMG metric ¼ a þ b⋅ Pavg þ c⋅Pavg 2 þ d⋅Ton⋅Pavg
þ e⋅Ton2 ⋅Pavg
The same analysis was done to relate center-of-mass
data to actuation timing and exoskeleton power:
Center‐of‐mass metric ¼ a þ b⋅ Pavg þ c⋅Pavg 2
þ d⋅Ton⋅Pavg
þ e⋅T on2 ⋅Pavg
Statistical tests for the effect of actuation timing and
exoskeleton power on metabolic cost, EMG metrics and
center-of-mass average rebound power were performed
through this regression analysis (P ≤ 0.05).

Results
Subjects walked in 10 powered exoskeleton conditions
(based on combinations of the four different actuation
timings (Earliest, Early, Late, Latest) and three different
exoskeleton power levels (Low, Medium, High)), a ZeroWork condition and a NormalWalking condition. The
distribution of actuation timing and exoskeleton power
shows that the desired parameter space was successfully
covered (Fig. 2) and that the powered conditions were
clearly distinguishable from each other. Earlier actuation

Table 1 Regression analysis results
Formula
(1)

ΔE = − 0.096 + 9.2 ⋅ Pavg − 0.49 ⋅ Ton ⋅ Pavg + 0.0055 ⋅ Ton ⋅ Pavg

(2)

ΔE = 0.0088 + 9.1 ⋅ Pavg + 5 ⋅ Pavg2 − 0.64 ⋅ Ton ⋅ Pavg + 0.0077 ⋅ Ton2 ⋅ Pavg

(3)

2

(0.89 ⋅ Pavg)

ΔE = − 10 + 10 ⋅ exp

Pavg − 0.62 ⋅ Ton ⋅ Pavg + 0.0075 ⋅ Ton ⋅ Pavg
2

R2

P

0.833

0.01

0.990

<0.001

0.988

<0.001

Results of three different regressions that were used as potential candidates to result in a good fit for the effect of actuation timing and exoskeleton power on
metabolic cost of exoskeleton walking with the resulting R2 and P-values
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timings resulted in an earlier onset of pneumatic muscle
force (Additional file 2: Figure S2) and an earlier onset
of exoskeleton torque (Fig. 3). Increased air pressure in
the pneumatic muscles (Additional file 2: Figure S2) increased exoskeleton peak torque in conditions with
more exoskeleton power (Fig. 3). This resulted in an
earlier plantarflexion onset with earlier actuation timings
and higher peak plantarflexion angles in conditions with
more exoskeleton power (Fig. 3). Step length (P = 0.01)
and toe-off timing (P = 0.01) showed small differences
between conditions but were very similar overall. Step
length was 0.68 ± 0.01 m on average across all conditions
and toe-off timing occurred at 62 ± 1% of stride on average across all conditions.
Subjects’ metabolic cost reached steady state in the last
two minutes of each walking condition (Additional file 3:
Figure S3). A significant difference was found for net
metabolic cost between conditions (P < 0.001). Net metabolic cost of all powered conditions was significantly lower
than that in the ZeroWork condition (4.03 ± 0.74 W∙kg−1)
(Fig. 4 and Additional file 4: Figure S4). The lowest net
metabolic cost was found in the Early-Medium condition
(3.16 ± 0.55 W∙kg−1), with a reduction of 21.4 ± 5.6% compared to ZeroWork and 12.3 ± 9.3% compared to NormalWalking (3.60 ± 0.74 W∙kg−1). In the Early-Medium
condition, actuation onset was 42.3 ± 0.8% of stride and
average power was 0.42 ± 0.03 W∙kg−1. The metabolic
penalty of wearing the exoskeleton in ZeroWork
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compared to NormalWalking was 11.6 ± 9.6%. Although
the metabolic cost of powered exoskeleton walking was
lower in almost all conditions compared to NormalWalking, only the difference in the Early-Medium condition was statistically significant (Fig. 4 and Additional
file 4: Figure S4). The ratio of the change in metabolic
rate to exoskeleton mechanical power for the EarlyMedium condition, was 2.1 ± 0.8. Higher ratios were
found in the Early-Low and Late-Low conditions, with
values of 3.1 ± 0.9 and 3.1 ± 1.4, respectively. Earlier or
later timings or higher amounts of exoskeleton power
resulted in lower ratios.
Regression analyses established strong relationships
between actuation timing (Ton), exoskeleton power
(Pavg) and the reduction in metabolic cost (ΔE). Consistent with the choice for a quadratic relationship for
both actuation timing and exoskeleton power (Table 1),
metabolic cost was higher in all Low and High conditions compared to the corresponding Medium conditions and metabolic cost was higher in all Earliest and
Late conditions compared to the Early condition (Fig. 4
and Additional file 4: Figure S4). The resulting regression for the metabolic cost was statistically significant (P
<0.001) and predicted experimental values well (R2 =
0.99) (Table 1). This 2D non-linear model combining actuation timing and average exoskeleton power therefore
provided a strong estimate of the reduction in metabolic
cost of walking with this exoskeleton. The regression

Fig. 3 Ankle joint angle, exoskeleton torque and exoskeleton power. Population averages, normalized from heel contact to heel contact for ankle
joint angle, exoskeleton torque and exoskeleton ankle joint mechanical power of the 10 powered conditions, the ZeroWork condition and the
NormalWalking condition. All powered conditions are shown in grey, with selected conditions in color. Subplots at top show which conditions are
plotted in color in each panel. The vertical grey line represents opposite heel contact
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Fig. 4 Net metabolic energy cost. Net metabolic cost is depicted
versus actuation timing and average positive exoskeleton power.
Metabolic cost for the powered exoskeleton conditions is expressed
as the reduction versus the ZeroWork condition. Repeated measures
ANOVA indicated significant differences in net metabolic energy
cost between conditions (P < 0.001). * indicates a statistically
significant reduction versus ZeroWork and ** indicates a statistically
significant reduction versus NormalWalking based on post-hoc
t-tests with Šídák-Holm correction (P ≤ 0.05). The percentages above
each condition are the statistically significant reductions in net
metabolic cost versus the ZeroWork condition. The percentages
underneath each condition (in bold) are the statistically significant
reductions in net metabolic cost versus NormalWalking. The surface
gradient is the result of a two-dimensional regression for which R2 is
provided (P < 0.001). The black dotted line indicates the metabolic
cost for NormalWalking and the black dashed line shows the
ZeroWork condition with the absolute net metabolic energy cost
given in numbers for both conditions

suggests metabolic cost is minimized when actuation
timing is 41% and exoskeleton power is 0.41 W∙kg−1,
close to the Early-Medium condition (Fig. 4). There did not
appear to be substantial interactions between optimal timing and optimal power; an onset of 41% stride minimized
cost for all power levels, and a power level of 0.41 W∙kg−1
minimized cost for all timings (Additional file 4: Figure S4).
Individual regressions sometimes deviated from the average
profile (Additional file 1: Figure S1).
Changes in patterns of muscle activity may help illustrate the function of specific muscles during walking and
how their activity changes with exoskeleton assistance
(Figs. 5, 6, 7, 8, 9 and 10). The tibialis anterior muscle
showed a large increase in muscle activity at the beginning of the stance phase and at the beginning of the
swing phase in the powered conditions (Fig. 5a). Peak
EMG during the beginning of the stance phase was significantly higher for almost all Medium and High power
conditions compared to ZeroWork and NormalWalking.
The regression analysis indicated that higher amounts of
exoskeleton power resulted in bigger increases in m.
tibialis anterior EMG (Fig. 5b). Peak EMG in the beginning of the swing phase was significantly higher for all
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powered conditions compared to ZeroWork and NormalWalking, with increases of more than 100% in several powered conditions. Regression analysis suggested
that more exoskeleton power resulted in higher m. tibialis anterior activity (Fig. 5c).
Exoskeleton assistance reduced m. soleus activity
during ankle push-off but seemed to increase EMG
activity during the swing phase (Fig. 6). Peak muscle
activity in the stance phase was reduced by more
than 30% compared to ZeroWork and NormalWalking with early actuation onset and high exoskeleton
power. The regression analysis indicated that m. soleus activity was most reduced in conditions with
early actuation timings and high amounts of power.
Soleus activity in the beginning of the swing phase
increased slightly, possibly the result of crosstalk with
the tibialis anterior muscle [34], as not much m. soleus activity is expected in this phase of the gait
cycle. This is further suggested by the similarity between the regression analysis for both m. soleus and
m. tibialis anterior peak EMG activity during the
swing phase. During push-off however, tibialis anterior muscle activity was negligible and the measured
signal probably originated only from the soleus
muscle.
Peak gastrocnemius medialis EMG during push-off
seemed to be reduced compared with both the NormalWalking and the ZeroWork condition (Fig. 7). However,
differences with the ZeroWork condition were not statistically significant. Several powered conditions showed
peak EMG activity that was more than 20% lower than
in the NormalWalking condition. Regression analysis
showed that peak m. gastrocnemius EMG was most reduced with late actuation timings and high amounts of
power.
Activity in the m. rectus femoris showed a peak in the
beginning of the stance phase for all conditions and in
the beginning of the swing phase in the NormalWalking
and ZeroWork conditions. No significant differences
were found for peak EMG between conditions in the beginning of the stance phase (P = 0.23). Peak EMG activity was substantially reduced in the swing phase (Fig. 8)
by as much as 40% compared to ZeroWork for all conditions. However, differences between powered conditions
were rather small, which was emphasized by the shape
of the regression which did not show a clear effect of actuation timing and exoskeleton power.
Activity in the m. biceps femoris showed a peak in the
end of the swing phase (Fig. 9). The EMG peak activity
during the swing phase seemed lower in the powered
conditions compared to the NormalWalking and ZeroWork conditions. Differences in peak EMG compared to
the ZeroWork condition were only statistically significant in a few conditions. Regression analysis showed a
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Fig. 5 Electromyography of the m. tibialis anterior. Time series show population averages for EMG of the m. tibialis anterior (TA) averaged for
the left and right leg and plotted from heel contact to heel contact (a). The grey vertical line represents opposite heel contact. All powered
conditions are shown in grey, with selected conditions in color. Subplots at top show which conditions are plotted in color. Blue rectangles show
the periods where a peak EMG value was analyzed. Repeated measures ANOVA indicated significant differences between conditions for the peak
EMG in the beginning of the stance phase (between 1 and 62% of the stride; P < 0.001) and for the peak EMG in the beginning of the swing
phase (between 62 and 80% of the stride; P < 0.001). The effect of actuation timing and exoskeleton power on peak EMG in the beginning of
the stance phase (b) and the beginning of the swing phase (c) is indicated by a regression analysis. The surface gradient is the result of a twodimensional regression for which R2 is provided for the peak EMG during the stance phase (P = 0.002) and during the swing phase (P < 0.001).
The black dotted line shows the NormalWalking condition and the black dashed line shows the ZeroWork condition with the absolute value for
both conditions. * indicates a statistically significant reduction versus ZeroWork and ** indicates a statistically significant reduction versus
NormalWalking based on post-hoc t-tests with Šídák-Holm correction (P ≤ 0.05)

strong relationship, with the highest reductions for intermediate timing values and Medium power levels.
Peak EMG activity during the stance phase in the m.
vastus lateralis and the m. gluteus maximus did not
show significant differences between the powered conditions and the NormalWalking or ZeroWork conditions
(Fig. 10).
Center-of-mass rebound power was significantly lower
in almost all powered conditions compared to the ZeroWork condition. The regression analysis showed that
average center-of-mass rebound work was reduced for
high levels of exoskeleton power and early timings
(Fig. 11) and had a pattern similar to that of the metabolic cost (Fig. 4).

Discussion
The overall goal of this study was to determine the relationship between metabolic cost, exoskeleton actuation
timing and exoskeleton power in an ankle-foot exoskeleton powered with pneumatic artificial muscles. We
found strong effects of both terms, well-characterized by
a two-dimensional quadratic function that suggested optimal actuation timing to be around 42% of stride and
optimal average exoskeleton power to be around
0.4 W∙kg−1 summed for both legs (Fig. 4). One of our
powered exoskeleton conditions, with actuation onset at
42.3 ± 0.8% of the stride and average exoskeleton power
of 0.42 ± 0.03 W∙kg−1 summed for both legs, indeed resulted in a reduction in net metabolic cost of 21.4 ± 5.6%
compared to walking with the exoskeleton without assistance from the pneumatic muscles. These reductions

are similar to the highest reported results to date [8].
Benefits were offset by a penalty of 11.6 ± 9.6% for wearing the exoskeleton while inactive, a higher penalty than
with some other recent exoskeletons [4, 5]. Optimal timing and power thereby reduced net metabolic cost by
12.3 ± 9.3% compared to normal walking, which is the
highest reported reduction for an ankle exoskeleton
compared to normal walking.
Actuation timing

Our regression analysis indicated an optimal actuation
onset of around 42% of the stride: when actuation timing
was independently varied, metabolic cost followed a convex pattern. In each of the Low, Medium and High
power conditions, metabolic cost had a U-shaped relationship with actuation timing (Fig. 4 and Additional file 4:
Figure S4). Given that there did not seem to be an interaction effect with exoskeleton power, optimal actuation
onset for an ankle exoskeleton with pneumatic muscles is
around 42% of the stride. The optimal actuation timing
that we found resulted from a trade-off between good
m. soleus assistance (with higher reductions for an earlier timing), m. gastrocnemius EMG assistance (with
higher reductions for a later timing) and low m. tibialis
anterior EMG resistance (with smaller increases for an
intermediate timing).
The actuation timing of the condition with the lowest
metabolic cost, e.g. with actuation timing onset at 42.3
± 0.8%, is close to the actuation timing with the lowest
metabolic cost of our previous study [3]. Mooney et al.
[4, 6] used a similar actuation timing for exoskeleton
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Fig. 6 Electromyography of the m. soleus. Time series show population averages for EMG of the m. soleus (SOL) averaged for the left and right
leg and plotted from heel contact to heel contact (a). The grey vertical line represents opposite heel contact. All powered conditions are shown in
grey, with selected conditions in color. Subplots at top show which conditions are shown in color. Blue rectangles show the periods where a peak
EMG value was analyzed. Repeated measures ANOVA indicated significant differences between conditions for the peak EMG in the stance
phase (between 1 and 62% of the stride; P < 0.001) and the peak EMG in the beginning of the swing phase (between 62 and 80% of the stride;
P < 0.001). The effect of actuation timing and exoskeleton power on peak EMG in the beginning of the stance phase (b) and the beginning
of the swing phase (c) is indicated by a regression analysis. The surface gradient is the result of a two-dimensional regression for which R2 is
provided for the peak EMG during the stance phase (P < 0.001) and during the beginning of the swing phase (P < 0.001). The black dotted line
shows the NormalWalking condition and the black dashed line shows the ZeroWork condition with the absolute value for both conditions.
*indicates a statistically significant reduction versus ZeroWork and ** indicates a statistically significant reduction versus NormalWalking based
on post-hoc t-tests with Šídák-Holm correction (P ≤ 0.05)

assistance, leading to high reductions in metabolic
cost. The observed optimum is on the other hand later
than the onset of torque in a passive exoskeleton with
a mechanical clutch that reduced the metabolic cost of
walking [5]. However, actuation with the exoskeleton
in the present study delivers mostly positive power,

whereas in the passive exoskeleton study the reduction
in metabolic cost is (at least partly) attributed to eccentric torque support during ankle dorsiflexion in the
single stance phase. Recently, Quinlivan et al. [8] also
found large reductions in the metabolic cost with an
earlier actuation onset timing. Their exoskeleton

Fig. 7 Electromyography of the m. gastrocnemius medialis. Time series show population averages for EMG of the m. gastrocnemius medialis
(GM) averaged for the left and right leg and plotted from heel contact to heel contact (a). The grey vertical line represents opposite heel contact.
All powered conditions are shown in grey, with selected conditions in color. Subplots at top show which conditions are shown in color. Blue
rectangles show the periods where a peak EMG value was analyzed. Repeated measures ANOVA indicated significant differences between
conditions for the peak EMG in the beginning of the stance phase (between 1 and 62% of the stride; P < 0.001). The effect of actuation timing
and exoskeleton power on peak EMG in the beginning of the stance phase (b) is indicated by a regression analysis. The surface gradient is the
result of a two-dimensional regression for which R2 is provided for the peak EMG during the stance phase (P < 0.001). The NormalWalking condition is
not visible as the value for NormalWalking is situated out of the range for which the regression is shown but the value of the NormalWalking condition
is shown. The black dashed line shows the ZeroWork condition with the absolute value. * indicates a statistically significant reduction versus ZeroWork
and ** indicates a statistically significant reduction versus NormalWalking based on post-hoc t-tests with Šídák-Holm correction (P ≤ 0.05)

Galle et al. Journal of NeuroEngineering and Rehabilitation (2017) 14:35

Page 11 of 16

Fig. 8 Electromyography of the m. rectus femoris. Time series show population averages for EMG of the m. rectus femoris (RF) averaged for the
left and right leg and plotted from heel contact to heel contact (a). The grey vertical line represents opposite heel contact. All powered conditions
are shown in grey, with selected conditions in color. Subplots at top show which conditions are shown in color. Blue rectangles show the periods
where a peak EMG value was analyzed. No significant differences were found between conditions for the first EMG peak during the stance phase
(between 1 and 62% of the stride; P = 0.23). Therefore, no regression analysis was done for this EMG metric. Repeated measures ANOVA indicated
significant differences between conditions for the peak EMG around toe-off (between 40 and 80% of the stride; P < 0.001). The effect of actuation
timing and exoskeleton power on peak EMG near toe-off (b) is indicated by a regression analysis. The surface gradient is the result of a twodimensional regression for which R2 is provided (P < 0.001). The black dotted line shows the NormalWalking condition and the black dashed line shows
the ZeroWork condition with the absolute value for both conditions. * indicates a statistically significant reduction versus ZeroWork and ** indicates a
statistically significant reduction versus NormalWalking based on post-hoc t-tests with Šídák-Holm correction (P ≤ 0.05)

assisted both the ankle and the hip joint, which makes
it difficult to compare results. Actuation torque
ramped in more slowly with that device, such that the
relatively low torques at the beginning of exoskeleton
assistance may have had little effect on the user. Our
observed optimum is on the other hand earlier than
with a unilateral prosthesis emulator, where an
optimum was found at 52% of stride or later [21]. This
difference could be due to the differences between
exoskeleton walking and prosthesis walking, the

difference between unilateral and bilateral assistance,
differences in the actuation profile or a combination
of these factors.
Average positive exoskeleton ankle power

Our regression analysis indicated an optimal amount of
average exoskeleton power around 0.4 W∙kg−1 summed
for both legs: when exoskeleton power was independently varied, metabolic cost followed a U-shaped pattern.
The exoskeleton power of the condition with the lowest

Fig. 9 Electromyography of the m. biceps femoris. Time series show population averages for EMG of the m. biceps femoris (BF) averaged for the
left and right leg and plotted from heel contact to heel contact (a). The grey vertical line represents opposite heel contact. All powered conditions
are shown in grey, with selected conditions in color. Subplots at top show which conditions are shown in color. Blue rectangles show the periods
where a peak EMG value was analyzed. Repeated measures ANOVA indicated significant differences between conditions for the peak EMG in the
swing phase (between 62 and 100% of the stride; P < 0.001). The effect of actuation timing and exoskeleton power on peak EMG in the swing
phase (b) is indicated by a regression analysis. The surface gradient is the result of a two-dimensional regression for which R2 is provided for the
peak EMG during the swing phase (P < 0.001). The NormalWalking condition is not visible as the value for NormalWalking is situated out of the
range for which the regression is shown but the value of the NormalWalking condition is shown. The black dashed line shows the ZeroWork
condition with the absolute value. * indicates a statistically significant reduction versus ZeroWork and ** indicates a statistically significant
reduction versus NormalWalking based on post-hoc t-tests with Šídák-Holm correction (P ≤ 0.05)
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Fig. 10 Electromyography of the m. vastus lateralis and m. gluteus maximus. Time series show population averages for EMG of the m. vastus
lateralis (VL) and the m. gluteus maximus (GL M) averaged for the left and right leg and plotted from heel contact to heel contact. The grey
vertical line represents opposite heel contact. All powered conditions are shown in grey, with selected conditions in color. Subplots at top show
which conditions are shown in color. Blue rectangles show the periods where a peak EMG value was analyzed. Repeated measures ANOVA
indicated significant differences between conditions for the EMG peak during the stance phase (between 1 and 62% of the stride; P = 0.05) for
the m. vastus lateralis, but post-hoc t-tests with Šídák-Holm correction did not show any significant difference between the powered conditions
and the NormalWalking condition or the ZeroWork conditon. Therefore, no regression analysis was done for this EMG metric. Repeated measures
ANOVA indicated no significant differences between conditions for the EMG peak during the stance phase (between 1 and 62% of the stride;
P = 0.95) for the m. gluteus maximus. Therefore, no regression analysis was done for this EMG metric

metabolic cost, e.g. with exoskeleton power of 0.42 ±
0.03 W∙kg−1 summed for both legs corresponds to
around 100% of the net biological ankle joint work during walking without exoskeleton assistance [10, 11].
Higher levels of average exoskeleton power resulted in
smaller reductions in metabolic cost, especially in the
earlier actuation onset timing conditions. With an exosuit that assisted both the ankle and the hip joints, an
inverse linear relationship was found between

exoskeleton power and the metabolic cost of walking
until average net exoskeleton power was 0.19 W∙kg−1
per leg [8]. This seems in accordance with our results,
with the addition that we found that higher amounts of
exoskeleton power did not result in further reductions
in the metabolic cost of walking. A similar trend was observed in a unilateral exoskeleton study, in which metabolic cost seemed to level off or worsen in the highest
exoskeleton work conditions [9]. Other recent

Fig. 11 Center-of-mass power calculations. Time series show population averages for center-of-mass power plotted from heel contact to heel
contact (a). The grey vertical line represents opposite heel contact. All powered conditions are shown in grey, with selected conditions in color.
Subplots at top show which conditions are shown in color. Blue rectangles show the periods where the rebound phase was present and where
the average center-of-mass power was calculated for the positive burst. Repeated measures ANOVA indicated significant differences between
conditions for the average center-of-mass power during this rebound phase (P < 0.001). This was calculated as the numerical integration of
rebound power, divided by stride time. The effect of actuation timing and exoskeleton power on average center-of-mass power is indicated by a
regression analysis (b). The surface gradient is the result of a two-dimensional regression for which R2 is provided (P < 0.001). The black dotted line
shows the NormalWalking condition and the black dashed line shows the ZeroWork value. * indicates a statistically significant reduction versus
ZeroWork and ** indicates a statistically significant reduction versus NormalWalking based on post-hoc t-tests with Šídák-Holm correction (P ≤ 0.05)
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simulations and experiments [5, 15, 16] have found that
‘more is not always better’ for several parameters of
walking (assistance), due to a trade-off between several
factors that have a positive or a negative effect on the
metabolic cost of walking. A similar trade-off seems
present in our EMG results. For the m. soleus and the
m. gastrocnemius we found that higher exoskeleton
power was better but for the m. tibialis anterior high
power was detrimental.
It must be mentioned that we chose a second order
relationship over an exponential relationship in our regression analysis (Table 1). This choice was based on
the fact that average metabolic cost was higher in all
High conditions compared to the corresponding
Medium conditions, which indicated that metabolic
cost had a U-shaped relationship with exoskeleton
power in each of the Earliest, Early and Late timing
conditions (Fig. 4 and Additional file 4: Figure S4). Due
to the small differences in exoskeleton power between
our Medium and High conditions, it is difficult to draw
strong conclusions. In prosthesis research [14, 35] an
exponential relationship was found for the reduction in
metabolic cost and average positive exoskeleton ankle
power until at least 200% of the positive work that is
delivered by the biological ankle joint during normal
walking. It is hard to estimate how the relationship
would extend when higher amounts of power are applied, especially in late actuation timings.
While we found an optimal amount of exoskeleton
power around 0.4 W∙kg−1, lower amounts of power also
resulted in a reduction in metabolic cost of 14 to 16%
compared to walking in the zero-work mode. In these
conditions, the ratio of change in metabolic rate to
mechanical power was much higher than in the metabolically optimal condition. This suggests that the assistance in conditions with lower amounts of power
(around 0.2 W∙kg−1) can be more efficient, which could
be important for autonomous devices where battery
weight is a concern.
Assistive mechanism

The extensive parameter sweep that we performed improves overall insights into the assistive mechanism of
ankle exoskeletons that result in a reduction in metabolic cost. Previous work suggested that exoskeletons
could reduce step-to-step transition costs [3], which
stem from the negative work performed in the collision
phase and the positive work to compensate for this energy loss, both serving to redirect the center-of-mass
from one arc to another [27]. Indeed, it has been shown
that ankle exoskeletons replace some push-off work [4].
However, while some studies have found a reduction in
contralateral collision during unilateral exoskeleton
walking [9], other studies with unilateral exoskeletons
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and prostheses have not found a reduction in collision
work [14, 21]. On a muscular level, we did not find reductions in activity of the m. gluteus maximus, the m.
biceps femoris, the m. vastus lateralis or the m. rectus
femoris during the collision phase, suggesting that costs
related to collision were not reduced. Several studies
have reported changes in metabolic cost in combination
with changes in rebound work instead of collision work
[5, 8, 9, 14, 28–30]. In this study we found a strong similarity between the optimal parameters for the reduction
in metabolic cost and for reduction in rebound work.
The rebound phase is often attributed to positive work
of the stance leg and to contralateral leg swing [26, 36].
We found indications of assistance in leg swing initiation
during exoskeleton assistance with a reduction in m. rectus femoris activity. One of the roles of the m. rectus
femoris during the end of stance and the initiation of
swing is to serve as a hip flexor to bring the swing leg
forward [37]. This suggests less involvement of hip and
knee musculature in leg swing during powered exoskeleton assistance. Several other studies have reported the
influence of ankle assistance on the knee and hip joints
[4, 12, 17, 18]. Similar findings were found in a prosthesis study [14], where ankle push-off work also implicated in assisting leg swing initiation. While we only
assisted the ankle joint, it is likely that the increased
plantarflexion and the higher plantarflexion velocity during push-off with exoskeleton assistance could influence
the following leg swing. This seems to coincide with
findings of Lipfert et al. [38], that linked the impulsive
ankle push-off in walking to initiation of leg swing. As
such, it seems that increased plantarflexion is an essential proviso for assisting leg swing initiation with an
ankle exoskeleton. Other studies with exoskeletons that
reduced metabolic cost and reported reduced knee and
hip work also showed increases in plantarflexion [4, 12,
18]. This could also explain why other exoskeletons that
imposed similar torque profiles but maintained normal
joint angles did not result in a reduction in the metabolic cost of walking [39]. It may therefore not be optimal to emulate the biological ankle kinematics.
Future work

Recent findings from simulations and experiments [5,
40] suggest that the metabolic cost of the plantarflexors
is not only related to the push-off but also to isometric
activity earlier in the stance phase. For example, reductions in metabolic cost of up to 7% are possible from
torque support during the beginning of the stance
phase [5]. A combination of replacing ankle joint work
during push-off, assisting leg swing initiation (as a direct result of ankle assistance or by assisting the hip
joint itself [41, 42]) like we did in our study and torque
support during the beginning of stance, as was done in
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the passive exoskeleton study [5], could potentially lead
to reductions in the metabolic cost of more than 25%,
especially because midstance torque support can lead
to inefficient, rapid shortening of plantarflexor muscles
during push-off [5]. Exoskeletons that can vary torque
and power in a more controlled way [43] could be used to
manipulate the exoskeleton power profile and further
focus on the combined assistance of torque support during stance and positive power assistance during push-off.
Because of the complexity of human locomotion, reducing the metabolic cost of walking with an exoskeleton is not straightforward. Due to the effect of
exoskeleton assistance on walking pattern (e.g. [3]), on
balance [44], on muscle activity (e.g. [10]), on elastic
stretch and recoil (e.g. [5]), on fascicle power (e.g. [45])
and many other factors, it is difficult to predict human
behavior resulting from exoskeleton assistance. One
way to explore this space is to perform parameter
sweep experiments in combination with supporting
measures to understand why a specific condition is
beneficial (e.g. [3, 8, 9, 14, 21]). These parameter sweep
studies will remain necessary in the future to establish
optimal assistance as the optimum will likely result
from a combination of factors. Another promising approach is direct optimization of metabolic rate using
human-in-the-loop optimization techniques [46–48].
At the moment experimental approaches are still preferred, as intuition is often deceiving and simulations
are not yet very reliable [49] because of the complex
human-exoskeleton interface. However, experimental
results from studies like this one can be used to improve musculoskeletal models.

Limitations

Our exoskeleton testbed was tethered to off-board hardware and power sources, while other exoskeletons have
shown reductions in metabolic cost for autonomous devices where all the hardware and power sources were
carried by the user [5, 6]. The large difference that we
found between powered exoskeleton walking and exoskeleton walking in zero-work mode suggests that if we
could apply our actuation profile with a lightweight autonomous exoskeleton [4–6, 8], reductions of more than
15% versus normal walking are possible. One possibility
might be to rely on the human joints to serve as hinges,
which shows promise [4, 6, 8].
Despite the recent introduction of autonomous exoskeletons [5, 6, 8] our exoskeleton testbed is still useful
as it allows manipulation of exoskeleton assistance
parameters in a broad range, which is important to improve the understanding of human-exoskeleton interaction. There is still a need for studies combining
metabolic measurements, EMG, kinematics and
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kinetics during exoskeleton walking in a broad range of
conditions to elaborate on these findings. Similar studies have improved insight into exoskeleton work and
torque support [8, 9], unilateral prosthesis walking [14]
and bilateral prosthesis walking [21].
One of the limitations of this study is that individual
subjects exhibited differences in their responses to exoskeleton assistance. We searched for one optimal actuation timing and optimal exoskeleton power, while this
sometimes seemed to differ between subjects. By using
individual optimizations, it may be possible to further
reduce metabolic cost. We found reductions of 26 ± 4%
for powered versus ZeroWork walking and of 17 ± 10%
for powered walking versus normal walking if we averaged the highest reductions from each subject.
We were unable to fully control the shape of the exoskeleton power curve and it is possible that other actuation parameters affect metabolic cost more strongly. For
example, our exoskeleton testbed was not able to deliver
sufficient power to elaborate the latest onset timing thoroughly. It would be useful to explore higher amounts of
exoskeleton power with late timing. A future approach
could be to evaluate the effect of the shape of the actuation profile on the metabolic cost of exoskeleton walking.

Conclusions
This study examined the independent effects of ankle exoskeleton actuation timing and average exoskeleton power
on the metabolic cost of walking. We showed that reductions in metabolic cost of 21% versus walking with the
exoskeleton in zero-work mode and 12% versus normal
walking without the exoskeleton are possible with optimal
actuation timing and power. Actuation timing showed an
optimum at 42% of the stride and average exoskeleton
power was optimal at around 0.42 W∙kg−1. The assistive
mechanisms leading to these reductions include reducing
muscular activity of the plantarflexors during push-off and
more proximal muscles during leg swing initiation.
Endnotes
1
Normal walking is used to refer to walking without
an exoskeleton. Active exoskeletons refer to exoskeletons
which use external energy to assist walking while passive
exoskeletons store and re-use energy which is generated
by the user and thus do not need external energy input.
Powered walking refers to walking with exoskeleton assistance (both for passive and active exoskeleton assistance).
Walking with the exoskeleton without assistance of the
device (e.g. with the assistive spring disengaged for passive
devices or without active assistance for active devices) is
referred to as walking with zero-work instead of
‘unpowered’ exoskeleton walking (e.g. [3, 10]) to avoid
confusion when concerning passive exoskeletons [5].
Tethered exoskeletons refer to a connection with off-
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board hardware or power source. Autonomous exoskeletons refer to devices were all hardware and power
sources are carried by the user.
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